Cargando…

Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review

Background and Purpose: The availability of oncology biosimilars is deemed as a fundamental strategy to achieve sustainable health care. However, there is scarce systematic evidence on economic effectiveness of cancer biosimilars. We aimed to synthesize evidence from pharmacoeconomic evaluation of o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Hui-Yao, Liu, Cheng-Cheng, Yu, Yue, Wang, Le, Wu, Da-Wei, Guo, Lan-Wei, Wang, Shu-Hang, Fang, Hong, Bai, Ying, Fang, Yuan, Fan, Qi, Sun, Chao, Wu, Ying, Shi, Ju-Fang, Ma, Fei, Tang, Yu, Dai, Min, Li, Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849203/ https://www.ncbi.nlm.nih.gov/pubmed/33536905 http://dx.doi.org/10.3389/fphar.2020.572569

Ejemplares similares

Grand Challenges in Pharmacoeconomics and Health Outcomes
por: Dubois, Dominique J.
Publicado: (2010)

Pharmacoeconomic studies in Nepal: the need of the hour
por: Acharya, Mahip
Publicado: (2014)

LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA(®) in Chinese healthy male subjects
por: Cao, Guoying, et al.
Publicado: (2023)

Light at the end of the tunnel?: The Great Indian Pharmacoeconomics story
por: Thakkar, Karan B., et al.
Publicado: (2013)

How Sensitive is Sensitivity Analysis?: Evaluation of Pharmacoeconomic Submissions in Korea
por: Bae, SeungJin, et al.
Publicado: (2022)

Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study
por: Wang, Fang, et al.
Publicado: (2023)

Worldwide experience with biosimilar development
por: McCamish, Mark, et al.
Publicado: (2011)

Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China
por: Wu, Qiyou, et al.
Publicado: (2023)

A Biosimilarity Study Between QX001S and Ustekinumab in Healthy Chinese Male Subjects
por: Gao, Lei, et al.
Publicado: (2021)

Pinelliae rhizoma alleviated acute lung injury induced by lipopolysaccharide via suppressing endoplasmic reticulum stress-mediated NLRP3 inflammasome
por: Wang, Ning-ning, et al.
Publicado: (2022)

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016)

Ginsenoside Rb1 Ameliorated Bavachin-Induced Renal Fibrosis via Suppressing Bip/eIF2α/CHOP Signaling-Mediated EMT
por: Ni, Yu-Hao, et al.
Publicado: (2022)

A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers
por: Wang, Jin, et al.
Publicado: (2019)

The safety and efficacy of remimazolam tosylate for induction and maintenance of general anesthesia in pediatric patients undergoing elective surgery: Study protocol for a multicenter, randomized, single-blind, positive-controlled clinical trial
por: Fang, Yu-Bo, et al.
Publicado: (2023)

Adapting Pharmacoeconomics to Shape Efficient Health Systems en Route to UHC – Lessons from Two Continents
por: Miot, Jacqui, et al.
Publicado: (2017)

Editorial: Pharmacoeconomics in the era of health technology assessment and outcomes research to prioritize resource use, innovation and investment
por: Girardin, François R., et al.
Publicado: (2023)

A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra(®)) in Chinese healthy subjects
por: Zhang, Hong, et al.
Publicado: (2021)

Creating China’s Biosimilar Drugs Regulatory System: A Calculated Approach
por: Yang, Jianhong, et al.
Publicado: (2022)

A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects
por: Zhang, Hong, et al.
Publicado: (2021)

A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men
por: Zhang, Hong, et al.
Publicado: (2021)

A Worldwide Bibliometric Analysis of Tetrandrine Research in Recent Two Decades
por: Yang, Guang, et al.
Publicado: (2022)

The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors
por: Fabiani, Claudia, et al.
Publicado: (2019)

Comparison of Postoperative Analgesic Effects Between Nalbuphine and Fentanyl in Children Undergoing Adenotonsillectomy: A Prospective, Randomized, Double-Blind, Multicenter Study
por: Chen, Fang, et al.
Publicado: (2020)

Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time Points
por: Su, Jinmei, et al.
Publicado: (2020)

The Clinical Implications of Nocebo Effects for Biosimilar Therapy
por: Colloca, Luana, et al.
Publicado: (2019)

Editorial: Biological drugs and biosimilars in autoimmune diseases
por: Wajda, Anna, et al.
Publicado: (2023)

Evidence of Chinese Herbal Medicine Use From an Economic Perspective: A Systematic Review of Pharmacoeconomics Studies Over Two Decades
por: Xiong, Xiaomo, et al.
Publicado: (2022)

Pim1 Kinase Inhibitors Exert Anti-Cancer Activity Against HER2-Positive Breast Cancer Cells Through Downregulation of HER2
por: Wang, Bo-Wei, et al.
Publicado: (2021)

Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects
por: Chen, Hanjing, et al.
Publicado: (2022)

Efficacy of Early Combination Therapy With Lianhuaqingwen and Arbidol in Moderate and Severe COVID-19 Patients: A Retrospective Cohort Study
por: Fang, Jie, et al.
Publicado: (2020)

Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies
por: Lee, Shu-Ping, et al.
Publicado: (2019)

A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects
por: Zhang, Hong, et al.
Publicado: (2020)

Essentials of pharmacoeconomics
por: Rascati, Karen L.
Publicado: (2014)

Principles of pharmacoeconomics /
Publicado: (1996)

Warfarin anticoagulation management during the COVID-19 pandemic: The role of internet clinic and machine learning
por: Dai, Meng-Fei, et al.
Publicado: (2022)

A Randomized, Double-Blind, Single-Dose Study Comparing the Biosimilarity of HOT-1010 With Bevacizumab (Avastin®) in Chinese Healthy Male Subjects
por: Huang, Kai, et al.
Publicado: (2021)

Nocebo in Biosimilars and Generics in Neurology: A Systematic Review
por: Spanou, Ioanna, et al.
Publicado: (2019)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)

Switching Among Biosimilars: A Review of Clinical Evidence
por: Allocati, Eleonora, et al.
Publicado: (2022)

Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
por: Barbier, Liese, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s51g6loe2c1gjl0kq36bjvr782